HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Polyradiculoneuropathy (Polyradiculoneuritis)

Diseases characterized by injury or dysfunction involving multiple peripheral nerves and nerve roots. The process may primarily affect myelin or nerve axons. Two of the more common demyelinating forms are acute inflammatory polyradiculopathy (GUILLAIN-BARRE SYNDROME) and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple peripheral nerves and spinal nerve roots.
Also Known As:
Polyradiculoneuritis; Polyradiculoneuritides; Polyradiculoneuropathies; Autoimmune Demyelinating Disease, Peripheral; Demyelinating Autoimmune Disease, Peripheral; Demyelinating Disease, Peripheral Autoimmune; Peripheral Autoimmune Demyelinating Disease
Networked: 332 relevant articles (16 outcomes, 24 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
2. Demyelinating Diseases (Demyelinating Disease)
3. Infections
4. Peripheral Nervous System Diseases (PNS Diseases)
5. Meningitis

Experts

1. Dispenzieri, Angela: 12 articles (01/2021 - 07/2011)
2. Dyck, P James B: 5 articles (12/2021 - 03/2010)
3. Viala, Karine: 5 articles (04/2020 - 07/2017)
4. Dubey, Divyanshu: 4 articles (12/2021 - 01/2018)
5. Klein, Christopher J: 4 articles (12/2021 - 01/2018)
6. Rajabally, Yusuf A: 3 articles (01/2022 - 11/2004)
7. Mauermann, Michelle L: 3 articles (12/2021 - 12/2012)
8. McKeon, Andrew: 3 articles (12/2021 - 01/2018)
9. Pittock, Sean J: 3 articles (12/2021 - 01/2018)
10. Ghafouri-Fard, Soudeh: 3 articles (10/2021 - 01/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Polyradiculoneuropathy:
1. Intravenous Immunoglobulins (IVIG)FDA Link
2. Proteins (Proteins, Gene)FDA Link
3. SteroidsIBA
4. Immunoglobulin G (IgG)IBA
5. AntibodiesIBA
6. Immunoglobulins (Immunoglobulin)IBA
7. AutoantibodiesIBA
06/01/2021 - "There are bunch of autoantibodies, particularly autoantibodies against proteins located at the node of Ranvier, have been discovered and transformed the clinical management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). "
01/01/2012 - "Because sural nerve biopsy performed prior to CHOP therapy revealed no infiltration of lymphoma cells, immune dysfunction mediated by some cytokine or unidentified autoantibody related to PTCL-NOS was thought to be involved in the polyradiculoneuropathy."
11/01/2018 - "IgM autoantibodies against neurofascin-155 were detected by ELISA in five patients, four with inflammatory demyelinating polyradiculoneuropathy (CIDP) and one with Guillain-Barré syndrome (GBS), and were confirmed by ELISA-based preabsorption experiments and Western blot. "
12/01/2016 - "Until now, the most popular autoantibodies have been contactin-1 and neurofascin-155 for chronic demyelinating polyradiculoneuropathy (CIDP), GM1-ganglioside for multifocal motor neuropathy, and myelin-associated glycoprotein for polyneuropathy associated with monoclonal gammopathy of unknown significance. "
09/01/2001 - "Six M-IgM autoantibody activity profiles have been described in correlation with distinct clinical syndromes: - the M-IgM autoantibody activity profile against the carbohydrate epitope common to the glycolipids SGPG and SGLPG and myelin associated glycoprotein (MAG) in chronic demyelinating sensitive and sensorimotor peripheral neuropathies (58 patients, 52%); - the M-IgM autoantibody activity profile against immunodominant GM1 in demyelinating pure motor neuropathies (9 patients, 8%); - the M-IgM autoantibody activity profile against immunodominant disialosylgangliosides in chronic demyelinating sensitive ataxic neuropathies (8 patients, 7%); - the M-IgM autoantibody activity profile against immunodominant GM2 in demyelinating motor polyneuropathies (3 patients, 2.5%); - the M-IgM autoantibody activity profile against immunodominant GD1a in pure motor polyneuropathies (2 patients, 2%); - the M-IgM autoantibody activity profile against immunodominant GT1b and polysialosylgangliosides in one acute polyradiculoneuropathy (1%). "
8. ParaproteinsIBA
9. Prednisone (Sone)FDA LinkGeneric
10. Cholecalciferol (Vitamin D3)FDA Link

Therapies and Procedures

1. Plasma Exchange
2. Plasmapheresis
3. Tonsillectomy
4. Hypnosis (Mesmerism)
5. Therapeutics